IN2014CN02972A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02972A
IN2014CN02972A IN2972CHN2014A IN2014CN02972A IN 2014CN02972 A IN2014CN02972 A IN 2014CN02972A IN 2972CHN2014 A IN2972CHN2014 A IN 2972CHN2014A IN 2014CN02972 A IN2014CN02972 A IN 2014CN02972A
Authority
IN
India
Prior art keywords
corneal
riboflavin
keratoconus
permeation
guarantee
Prior art date
Application number
Other languages
English (en)
Inventor
Fulvio Foschini
Marcello Stagni
Giulio Luciani
Pierre Roy
Original Assignee
Sooft Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sooft Italia Spa filed Critical Sooft Italia Spa
Publication of IN2014CN02972A publication Critical patent/IN2014CN02972A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2972CHN2014 2011-10-25 2012-10-24 IN2014CN02972A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000560A ITRM20110560A1 (it) 2011-10-25 2011-10-25 Migliorata composizione di cross-linking per il trattamento del cheratocono mediante iontoforesi
PCT/IT2012/000324 WO2013061350A1 (fr) 2011-10-25 2012-10-24 Composition de réticulation améliorée administrée par ionophorèse, utile pour le traitement du kératocône

Publications (1)

Publication Number Publication Date
IN2014CN02972A true IN2014CN02972A (fr) 2015-07-03

Family

ID=45315962

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2972CHN2014 IN2014CN02972A (fr) 2011-10-25 2012-10-24

Country Status (16)

Country Link
US (1) US9439908B2 (fr)
EP (1) EP2770979B1 (fr)
JP (1) JP5913606B2 (fr)
KR (1) KR101837238B1 (fr)
AU (1) AU2012327916B2 (fr)
BR (1) BR112014009761B8 (fr)
CA (1) CA2851331C (fr)
EA (1) EA026703B1 (fr)
ES (1) ES2546263T3 (fr)
IL (1) IL232194A (fr)
IN (1) IN2014CN02972A (fr)
IT (1) ITRM20110560A1 (fr)
MX (1) MX342930B (fr)
PT (1) PT2770979E (fr)
RS (1) RS54139B1 (fr)
WO (1) WO2013061350A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP2663281B1 (fr) 2011-01-12 2016-08-10 Sooft Italia Spa Administration à la cornée d'agents de réticulation par ionophorèse pour le traitement de kératocône et compositions ophtalmologiques associées
WO2013148896A1 (fr) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Solutions de traitement oculaire, dispositifs d'administration et procédés améliorant l'administration
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
US9931199B2 (en) * 2014-05-05 2018-04-03 Roberto Gustavo ALBERTAZZI Methods and apparatus for treating keratoconus
CN108025011A (zh) 2015-07-21 2018-05-11 艾维德洛公司 用光敏剂治疗眼睛的系统和方法
WO2017180851A1 (fr) 2016-04-13 2017-10-19 Avedro, Inc. Systèmes et procédés d'administration de médicaments à un œil

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030023228A1 (en) * 2001-07-20 2003-01-30 Parkinson Thomas M. Ocular iontophoretic device and method for using the same
ITRM20070356A1 (it) * 2007-06-26 2008-12-27 Sooft Italia Srl Soluzione oculare sterile monouso e suo procedimento di produzione per il cross linking corneale del cheratocono
IT1393402B1 (it) * 2008-08-28 2012-04-20 Sooft Italia Spa Uso di enhancer eventualmente con riboflavina, nonche' relative composizioni oftalmiche per cross-linking corneale del cheratocono o di altre patologie ectasiche corneali
EP2289937A1 (fr) 2009-08-24 2011-03-02 Wilfried Stücker Production d'anticorps monoclonaux in vitro
WO2011130356A2 (fr) * 2010-04-13 2011-10-20 Avedro, Inc. Systèmes et procédés pour activer une réticulation dans un œil

Also Published As

Publication number Publication date
KR101837238B1 (ko) 2018-03-09
MX342930B (es) 2016-10-19
BR112014009761B8 (pt) 2022-09-06
BR112014009761B1 (pt) 2022-05-24
BR112014009761A2 (pt) 2017-04-25
JP2014530904A (ja) 2014-11-20
CA2851331C (fr) 2019-11-12
MX2014004297A (es) 2014-07-24
US9439908B2 (en) 2016-09-13
CA2851331A1 (fr) 2013-05-02
IL232194A0 (en) 2014-06-30
WO2013061350A1 (fr) 2013-05-02
EP2770979A1 (fr) 2014-09-03
PT2770979E (pt) 2015-10-07
EP2770979B1 (fr) 2015-07-08
CN104023706A (zh) 2014-09-03
AU2012327916A1 (en) 2014-05-22
AU2012327916B2 (en) 2016-04-21
EA201490845A1 (ru) 2014-07-30
KR20140080553A (ko) 2014-06-30
RS54139B1 (en) 2015-12-31
ITRM20110560A1 (it) 2013-04-26
JP5913606B2 (ja) 2016-04-27
IL232194A (en) 2016-09-29
US20140303173A1 (en) 2014-10-09
ES2546263T3 (es) 2015-09-22
EA026703B1 (ru) 2017-05-31

Similar Documents

Publication Publication Date Title
IN2014CN02972A (fr)
IL227412A (en) Administration of cross-materials to corne by iontophoresis for the treatment of keratoconus and ophthalmic preparations for this purpose
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
NZ704247A (en) Compositions and treatment for eye diseases and disorders
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
IN2014DN09594A (fr)
TN2014000356A1 (en) Heterocyclyl compounds as mek inhibitors
EA028156B9 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
MY171920A (en) Prevention and treatment of ocular conditions
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
EP2490700A4 (fr) Composition de soin externe pour la peau comprenant un sel et du sucre en tant que principes actifs pour prévenir et traiter la vaginose et utilisation de cette composition
PH12015500653A1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
NZ766141A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
BR112015004469A2 (pt) sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares
WO2014071168A3 (fr) Administration d'inhibiteurs de la signalisation tgfbêta, dérivés de benzothiazépine ou combinaisons de ceux-ci pour améliorer la fonction musculaire chez des patients cancéreux
IN2014DN09437A (fr)
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
MX2013008635A (es) Mejoras de y relacionadas con composiciones.
WO2016030899A8 (fr) Méthodes de traitement de la sclérose latérale amyotrophique
PH12019501785A1 (en) Intranasal composition comprising betahistine
MX2015009414A (es) Agentes analgesicos oculares topicos.